MEI Pharma Inc.

(MEIP) Trade

By |

Profile

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. Geographically, all the business activities function through the region of the United States.

Contact Information

Website: www.meipharma.com
Email: investor@meipharma.com
Main Phone: +1 858 369-7100
Address: 11455 El Camino Real
Address 2: Suite 250
State: CA
City / Town: San Diego
Country: US
Postal Code: 92130

Issuer Information

Exchange: NSC
CEO: Daniel P. Gold
Employees: 51
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. Geographically, all the business activities function through the region of the United States.

Contact Information

Website: www.meipharma.com
Email: investor@meipharma.com
Main Phone: +1 858 369-7100
Address: 11455 El Camino Real
Address 2: Suite 250
State: CA
City / Town: San Diego
Country: US
Postal Code: 92130

Issuer Information

Exchange: NSC
CEO: Daniel P. Gold
Employees: 51
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 3.54 $ 0.29 (8.77%)
Last Price 3.54 Change $ 0.29 Change % 8.77 Tick N/A
Bid 3.30 Bid Size 500.00 Ask 3.48 Ask Size 2,300.00
Open 3.29 High 3.57 Low 3.25 Prev Close 3.25
Last Trade Volume 2 mi 52 Wk Hi 4.46 52 Wk Low 0.73
Market Cap 397.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 112,522,001.00 EPS (TTM) -0.53 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 13
Number of Buys 0 12
Number of Sells 0 1
Net Activity 0 968333
Last 10 Buys Shares
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Charles V. Baltic 1,000
Last 10 Sell Shares
Charles V. Baltic 1,000
Philippe O. Chambon 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 4.5 4.5 4.5 11
Low Target Price Estimate 2.5 2.5 2.5 2.5
Mean Target Price Estimate 3.17 3.17 3.17 6
Standard Deviation 1.15 1.15 1.15 4.44
Date of Most Recent Estimate 05/15/18 05/15/18 05/15/18 06/06/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 1 1 1
Moderate Buy 0 0 0 0
Hold 1 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 2.33 2.33 2.33